January 11, 2017 / 4:55 PM / in 9 months

BRIEF-Abbvie sees 2017 adjusted EPS growth 13-15 percent

Jan 11 (Reuters) - Abbvie Inc

* Abbvie sees 2017 adjusted EPS growth of 13-15 percent - JP Morgan Healthcare Conference

* Abbvie CEO says no product price increases to exceed single digits percentage

* Abbvie CEO says still sees annual Humira sales exceeding $18 billion by 2020

* Abbvie sees at least 7 drugs in clinical trials from Stemcentrx in 2017

* Abbvie CEO says has 8 near-term growth assets worth $25-$30 billion Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below